TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18262125

Group type: EXPERIMENTAL
Intervention: Forward Planned Intensity Modulated Radiotherapy (FPIMRT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional Wedge Techniques (CW)
Number of subjects: 43
Study: 16836774

Group type: EXPERIMENTAL
Intervention: Child-friendly constraint-induced movement therapy (CI therapy); 6 hours per day for 10 out of 12 consecutive days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Child-friendly constraint-induced movement therapy (CI therapy)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 22
Study: 12015761

Group type: EXPERIMENTAL
Intervention: THP (30 mg/30 mL of normal saline) administered into the bladder within 6 hours after TUR‐Bt
Number of subjects: 170

Group type: COMPARATOR
Intervention: TUR‐Bt alone
Number of subjects: 170
Study: 10523398

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8750123

Group type: EXPERIMENTAL
Intervention: Blood retrieved using the Stryker Consta Vac system
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postoperative plasma concentrations of IL-6
Number of subjects: 10

Group type: COMPARATOR
Intervention: Initial portion of drainage blood from the surgical area
Number of subjects: 10
Study: 2033528

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) rinse, 15 ml b.i.d. for 7 weeks (2 weeks before crown preparation, 3 weeks during provisional crown placement, 2 weeks after definitive crown cementation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normal oral hygiene without CHX)
Number of subjects: 30
Study: 7319758

Group type: EXPERIMENTAL
Intervention: Pure meglumines and contrast media with low osmolality
Number of subjects: 72

Group type: COMPARATOR
Intervention: Variation of the anionic component
Number of subjects: 72
Study: 6145480

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31410618

Group type: EXPERIMENTAL
Intervention: VITAL Start (VS)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 306
Study: 29233673

Group type: EXPERIMENTAL
Intervention: DFC traction-assisted ESD (DFC-ESD)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: DFC traction-assisted ESD (DFC-ESD) for lesions in the greater curvature of the upper or middle stomach
Number of subjects: 640

Group type: COMPARATOR
Intervention: Conventional ESD for lesions in the greater curvature of the upper or middle stomach
Number of subjects: 640
Study: 26654154

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 600 mg, three times a day for 24 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Metformin 500 mg, three times a day for 24 weeks
Number of subjects: 94
Study: 24928634

Group type: EXPERIMENTAL
Intervention: EGFR stages >90 ml min‐1 1.73 m‐2
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: EGFR stages <60 ml min‐1 1.73 m‐2
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: EGFR stages <45 ml min‐1 1.73 m‐2
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: EGFR impairment
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: EGFR stages 3b and 4
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: EGFR correlation
Number of subjects: 2323
Study: 21705148

Group type: EXPERIMENTAL
Intervention: Listening to relaxing music
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Sitting and reading magazines
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sitting in the waiting-room
Number of subjects: 154
Study: 20486374

Group type: EXPERIMENTAL
Intervention: Rotation‐traction (Group A)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Rotation‐turn manual reduction (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Traction (Group C)
Number of subjects: 300
Study: 17612846

Group type: EXPERIMENTAL
Intervention: Public insurance
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: No insurance
Number of subjects: 2541

Group type: COMPARATOR
Intervention: Private insurance
Number of subjects: 2541
Study: 16247062

Group type: EXPERIMENTAL
Intervention: Epley procedure with self-treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epley procedure alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: self-treatment
Number of subjects: 80
Study: 12417776

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated scalpel (UT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy with cold steel instruments (BT)
Number of subjects: 30
Study: 10939030

Group type: EXPERIMENTAL
Intervention: Epirubicin 150 mg/m2-cisplatin (group A)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Epirubicin 180 mg/m2-cisplatin (group B)
Number of subjects: 159
Study: 8748403

Group type: EXPERIMENTAL
Intervention: Daily lithium carbonate treatment (700 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alternate-day lithium carbonate treatment (1200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 1710167

Group type: EXPERIMENTAL
Intervention: ThioTEPA at 75 mg/m2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ThioTEPA at 65 mg/m2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ThioTEPA (general)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ThioTEPA (in previously treated ovarian cancer patients)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ThioTEPA pharmacokinetics
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: TEPA pharmacokinetics
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ThioTEPA and TEPA
Number of subjects: 27
Study: 7018798

Group type: EXPERIMENTAL
Intervention: Methandienone (100 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31017453

Group type: EXPERIMENTAL
Intervention: Traditional and Complementary Medicine (T&CM) interventions in addition to nicotine replacement therapy (NRT) and counseling
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT) and counseling
Number of subjects: 41
Study: 30029708

Group type: EXPERIMENTAL
Intervention: Communication Enhancement Program (CEP-S), 10 sessions over 5 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study: 27570900

Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT) - 12 sessions
Number of subjects: 12
Study: 24626435

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 214

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 214
Study: 22755543

Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sevoflurane plus low-dose remifentanil (Group SR)
Number of subjects: 50
Study: 20171136

Group type: EXPERIMENTAL
Intervention: Standardized simulated palpation training (8-10 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study: 18041570

Group type: EXPERIMENTAL
Intervention: 4 ml/kg of hypertonic-hyperoncotic solution (7.2% NaCl/10% dextran)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% NaCl (control group)
Number of subjects: 40
Study: 16120066

Group type: EXPERIMENTAL
Intervention: Indinavir alone or in combination with ritonavir
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Indinavir with efavirenz or nevirapine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Indinavir in female patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Indinavir pharmacokinetics
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ritonavir boosting
Number of subjects: 102
Study: 12398170

Group type: EXPERIMENTAL
Intervention: Prefabricated high precious metal post with cast core (group A)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Zirconia post with a prefabricated bonded ceramic core (group B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Resin‐ceramic interpenetrating phase composite post with a prefabricated bonded ceramic core (group C)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: No coronoradicular reinforcement (group D)
Number of subjects: 4
Study: 10599886

Group type: EXPERIMENTAL
Intervention: Wild-type IL-4 receptor
Number of subjects: 203

Group type: COMPARATOR
Intervention: IL-4R alpha variant Q576R
Number of subjects: 203
Study: 7476738

Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia using N2O:O2, halothane, d‐tubocurarine (n = 11)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia using N2O:O2, halothane, d‐tubocurarine, and supplemented with epidural analgesia (EA) (n = 11)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) using ketamine 10‐30 ug.kg‐1.min‐1, propofol 2 mg.kg‐1.h‐1, d‐tubocurarine, and supplemented with continuous EA (n = 6)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TIVA using ketamine 20‐50 ug.kg‐1.min‐1, midazolam in increments of 1.5 to 5 mg, and supplemented with intermittent EA (n = 5)
Number of subjects: 33
Study: 1788149

Group type: EXPERIMENTAL
Intervention: DDAVP (0.6 ml intranasal dose, 60 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6752876

Group type: EXPERIMENTAL
Intervention: Pirprofen (800 mg/day)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Ketoprofen (300 mg/day)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Pirprofen
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 227
Study: 31670173

Group type: EXPERIMENTAL
Intervention: Exercise informatics program
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual post-surgery care
Number of subjects: 88
Study: 30176553

Group type: EXPERIMENTAL
Intervention: BCS plus postoperative radiation therapy (XRT)
Number of subjects: 381

Group type: COMPARATOR
Intervention: BCS alone
Number of subjects: 381
Study: 27078496

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 25259787

Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Carbohydrate modified diet (D)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Metformin plus low-dose rosiglitazone (MR)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Subset of subjects with weight loss
Number of subjects: 46
Study: 22215883

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy (RT) with temozolomide (TMZ)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Radical radiotherapy (RT) alone
Number of subjects: 273
Study: 21180001

Group type: EXPERIMENTAL
Intervention: RelyX ARC (ARC, 3M ESPE) with 32% phosphoric acid treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (PF, Kuraray)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (UN, 3M ESPE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (abraded with #600‐grit SiC paper)
Number of subjects: 45
Study: 17708284

Group type: EXPERIMENTAL
Intervention: Low-dose anticancer drugs (MMC 2-8 mg, EPI 5-10 mg, CBP 100 mg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional-dose anticancer drugs (MMC 10 mg, EPI 40 mg, CBP 300 mg)
Number of subjects: 112
Study: 16464426

Group type: EXPERIMENTAL
Intervention: Nonrandomized intervention studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methodological tools used in randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allocation mechanism
Number of subjects: 0
Study: 12172338

Group type: EXPERIMENTAL
Intervention: Reboxetine 8 to 10 mg per day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 9
Study: 9814503

Group type: EXPERIMENTAL
Intervention: B7.1 expression on thyroid follicular cells in Hashimoto's thyroiditis (HT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokines IL1beta and LPS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-B7.1 mAb
Number of subjects: 0
Study: 8271293

Group type: EXPERIMENTAL
Intervention: 25 mg of beta carotene per day
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: 1 g ascorbic acid plus 400 mg alpha tocopherol per day
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: All three agents combined (25 mg beta carotene, 1 g ascorbic acid, 400 mg alpha tocopherol)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Ascorbic acid plus vitamin E
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Beta carotene alone
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: All three agents combined
Number of subjects: 505
Study: 2536257

Group type: EXPERIMENTAL
Intervention: Dideoxycytidine 0.06 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dideoxycytidine 0.03 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dideoxycytidine 0.01 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dideoxycytidine 0.005 mg/kg
Number of subjects: 61
Study: 29330230

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including bimonthly behavioural counselling, sit-stand desk attachment, wrist-worn activity-prompting device, cognitive behavioural therapy for LBP self-management
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 26963746

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 22
Study: 24933798

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (8% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Dentifrice (silica-based with 1450 ppm fluoride as sodium monofluorophosphate)
Number of subjects: 24
Study: 22800624

Group type: EXPERIMENTAL
Intervention: Low-dose iron supplementation (1 mg×kg⁻¹×d⁻¹) for 2 months
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Iron supplementation group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Boys (age 6 months)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Girls (age 6 months)
Number of subjects: 123
Study: 20545479

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Unfavorable comorbidities (higher age, diabetes, lower hemoglobin levels, lower eGFR)
Number of subjects: 412
Study: 18261779

Group type: EXPERIMENTAL
Intervention: Systolic slope of the ICP waveform during inspiration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Systolic slope of the ICP waveform during expiration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Correlation of ICP slope with simultaneous ICP
Number of subjects: 6
Study: 17121051

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (oxygenated blood alone)
Number of subjects: 22
Study: 12954695

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adrenaline
Number of subjects: 0
Study: 10816626

Group type: EXPERIMENTAL
Intervention: Single-layer continuous anastomosis
Number of subjects: 132

Group type: COMPARATOR
Intervention: Two-layer interrupted anastomosis
Number of subjects: 132
Study: 8783398

Group type: EXPERIMENTAL
Intervention: Electron field directed to the tumour bed only (LF group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Megavoltage radiation to encompass the whole breast and regional nodes (WF group)
Number of subjects: 0
Study: 7962932

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 0.86% benzyl alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plain 1% lidocaine
Number of subjects: 20
Study: 3579819

Group type: EXPERIMENTAL
Intervention: Alcohol at ground level (100-proof vodka mixed with juice, 2.2 ml X kg-1 of body weight)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Simulated altitude (12,500 ft) with alcohol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo at ground level
Number of subjects: 17

Group type: COMPARATOR
Intervention: Simulated altitude (12,500 ft) without alcohol (placebo)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ground level without alcohol (placebo)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Simulated altitude (12,500 ft)
Number of subjects: 17
Study: 31840620

Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) at 10 mg FA/kg dietary DM
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Branched-chain volatile fatty acids (BCVFA) at 5 g BCVFA/kg dietary DM
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined addition of FA and BCVFA (10 mg/kg DM of FA and 5 g/kg DM of BCVFA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (without additives)
Number of subjects: 36
Study: 29361929

Group type: EXPERIMENTAL
Intervention: Participation in the PACE-UP trial
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Men
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Individuals under 55 years
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Most deprived quintile
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Asian individuals
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Black individuals
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Individuals with co-morbidities or health limitations
Number of subjects: 1150
Study: 28039501

Group type: EXPERIMENTAL
Intervention: Dexamethasone-Dimenhydrinate (group DD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexamethasone-Ondansetron (group DO)
Number of subjects: 60
Study: 26783728

Group type: EXPERIMENTAL
Intervention: Online intervention (self-help)
Number of subjects: 81
Study: 23475448

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO), twice-daily sessions for 90 minutes at 2.5 ATA, 5 days a week for 2 weeks.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (control group), including offloading, wound debridement, and glucose control.
Number of subjects: 36
Study: 21981360

Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser treatment (once weekly)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser treatment (twice weekly)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 38
Study: 19769421

Group type: EXPERIMENTAL
Intervention: Topical benzocaine 20%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of lidocaine, tetracaine, and phenylephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical anesthetics (both)
Number of subjects: 0
Study: 16776926

Group type: EXPERIMENTAL
Intervention: Guanfu Base A (GFA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 201
Study: 15564204

Group type: EXPERIMENTAL
Intervention: Itraconazole plus lactobacillus preparation for 8 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Lactobacillus preparation alone for 8 weeks
Number of subjects: 2
Study: 11737381

Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen (Remune)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Adjuvant control
Number of subjects: 252
Study: 8583814

Group type: EXPERIMENTAL
Intervention: St. Jude Medical valve (n = 9)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CarboMedics valve (n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dobutamine infusion
Number of subjects: 19
Study: 1858490

Group type: EXPERIMENTAL
Intervention: Biparietal Diameter (BPD) estimates
Number of subjects: 541

Group type: COMPARATOR
Intervention: Last Menstrual Period (LMP) estimates
Number of subjects: 541
Study: 6228469

Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine (3 micrograms-HBsAg)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine
Number of subjects: 800
Study: 31298784

Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Nalmefene 10 mg
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 29346851

Group type: EXPERIMENTAL
Intervention: Nurse-led school-based sun protection programme (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 80
Study: 26475142

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 24187861

Group type: EXPERIMENTAL
Intervention: Integrated Chinese-Western therapy (injection and prescriptions of Chinese medicine based on Traditional Chinese Medicine syndrome differentiation, combined with Western treatment)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Western therapy alone (chemotherapy, supportive treatment, and symptomatic treatment)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Integrated Chinese-Western therapy
Number of subjects: 98
Study: 21264527

Group type: EXPERIMENTAL
Intervention: Anti-adrenergic medications
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 303
Study: 19930059

Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17622501

Group type: EXPERIMENTAL
Intervention: Hand searching in 14 surgical journals
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Hand searching project
Number of subjects: 1152
Study: 15111772

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m(2)) followed by Paclitaxel (200 mg/m(2) over 3 h)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m(2)) followed by Cyclophosphamide (600 mg/m(2))
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both AT and AC regimens
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: AT regimen
Number of subjects: 91
Study: 11575230

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 27

Group type: COMPARATOR
Intervention: Real acupuncture and Sham acupuncture
Number of subjects: 27